Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901574 | 0.87 | KDM4E (0.55) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1422234 | 0.87 | LMNA (0.74) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3455040 | 0.84 | GFER (0.62) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL14087050 | 0.84 | KDM4E (0.67) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9832171 | 0.84 | KDM4E (0.67) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL11156912 | 0.84 | SHMT1 (0.62) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5717700 | 0.81 | KDM4E (0.78) | KDM4EMEN1LMNASMN1; SMN2GAA | |
| SCHEMBL18997274 | 0.80 | KDM4E (0.66) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL19049510 | 0.80 | KDM4E (0.62) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL12851276 | 0.80 | KDM4E (0.74) | KDM4EMEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | claimed |
| CN-116262675-B | Method for preparing malononitrile oxime ether compound | 沈阳中化农药化工研发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| CN-116262675-A | Method for preparing malononitrile oxime ether compound | 沈阳中化农药化工研发有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | BASF SE (DE) | 2021-05-20 | — | — | US | disclosed |
| CN-103781768-B | Pde10 regulator | 霍夫曼-拉罗奇有限公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-2753604-B1 | PDE10 MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2574607-A1 | PDE10 modulators | F. Hoffmann-La Roche AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| WO-2013034506-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | disclosed |
| EP-2295444-A2 | Lipopeptides as antibacterial agents | Cubist Pharmaceutical Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | KDM4E 1933/4885MEN1 1203/4885KMT2A 2890/4885 |
| US-20210145002-A1 | PYRIDINE AND PYRAZINE COMPOUNDS | NDUFS5, IL5, NDUFS4 | KDM4E 1933/4885MEN1 1203/4885KMT2A 2890/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885MEN1 2872/4885KMT2A 2302/4885 |
| US-20130059833-A1 | PDE10 MODULATORS | PDE10A, PDE5A, PDE2A | KDM4E 1461/4885MEN1 2291/4885KMT2A 2193/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885MEN1 2872/4885KMT2A 2302/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | KDM4E 1358/4885MEN1 2870/4885KMT2A 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.